CD79B Y196 mutation is a potent predictive marker for favorable response to R‐MPV in primary central nervous system lymphoma
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Medicine"
DOI: 10.1002/cam4.5512
Abstract: Rituximab, high‐dose methotrexate (HD‐MTX), procarbazine and vincristine (R‐MPV), has significantly prolonged the survival of patients with primary central nervous system lymphoma (PCNSL), but predictive factors for response to R‐MPV have not yet been investigated. Herein,… read more here.
Keywords: primary central; mpv; central nervous; system lymphoma ... See more keywords